Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir.

Abstract excerpt

Hepatitis C virus (HCV) infection is a leading cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma worldwide. Two first-generation protease inhibitors, telaprevir and boceprevir, have recently been approved for the treatment of chronic hepatitis C genotype 1. Triple therapy comprising pegylated interferon-α, ribavirin and telaprevir or boceprevir increases sustained virological response rates...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antiviral Agents
• Share to Dose-Response Relationship, Drug
• Share to Drug Therapy, Combination
• Share to Hepacivirus
• Share to Hepatitis C, Chronic
• Share to Oligopeptides
• Share to Proline
• Share to Protease Inhibitors